Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Inhalation Sciences AB (ISAB) has received a new order worth 53,000 Euro from a regular client - a large global player in the field of inhaled therapies with a strong development pipeline based in Europe. The order is for additional modules and accessories that will expand the client's two existing PreciseInhale systems.
The client is a loyal ISAB customer, with two PreciseInhale systems in place. The client's team carry out advanced in vivo work on New Chemical Entities, using the highly accurate preclinical data generated by PreciseInhale to significantly reduce risk in the later clinical stages of development of its inhaled therapies.
Predicting and preventing failure at the preclinical stage, a relatively inexpensive stage of drug development, can produce enormous savings for companies in a market where the cost of developing drugs can easily run into billions of dollars (a 2020 study estimated the average cost of getting a new drug into the market to be 1.3 BUSD [1]).
CEO Manoush Masarrat: "This new order speaks to the great value our technology delivers to customers and how that value can keep growing with the system. PreciseInhale is a truly flexible, multi-modular system that can deliver highly accurate data across a range of in vitro and in vivo exposure modules, sourced from dry powder, inhaled or nebulized aerosols. We are pleased to see the great value PreciseInhale continues to deliver to our client."